Brief: Bellerophon Reports 2022 Loss Per Share Of $2.08
31/03/2023 13:32
March 31 (Reuters) - Bellerophon Therapeutics Inc
BLPH.O :
* BELLEROPHON PROVIDES CLINICAL PROGRAM UPDATE AND REPORTS
FULL-YEAR 2022 FINANCIAL RESULTS
* BELLEROPHON THERAPEUTICS INC FY LOSS PER SHARE $2.08
* BELLEROPHON THERAPEUTICS INC - COMPLETED ENROLLMENT IN
INOPULSE®
REBUILD PHASE 3 TRIAL; PIVOTAL TOP-LINE DATA EXPECTED IN
MID-2023
* BELLEROPHON THERAPEUTICS INC - AS OF DECEMBER 31, 2022,
HAD
UNRESTRICTED CASH AND CASH EQUIVALENTS OF $6.9 MILLION
Source text for Eikon: ID:nGNX8GVPjJ
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen